The ratings of three Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More
Will Gold’s Miserable First Half of 2013 Linger Into the Second Half?
Gold spent the first half of 2013 diving from the $1,700 level to around $1,200. But will the yellow metal continue its a downward spiral for the next six months? More
‘Dethroning the King’ Displays M&A’s Intricate Web — Summer Reading
'Dethroning the King' -- which details InBev's 2008 acquisition of Anheuser-Busch -- is the perfect primer on the egos, greed and dealmaking of Wall Street. More
12 “Triple F” Stocks to Sell
This week, 12 stocks get F's ("strong strong") in Portfolio Grader's three main grading categories, Total Grade, Overall Fundamental Grade, and Quantitative Grade. More
The Best & Worst ETFs in 2013’s First Half
Some of the market's biggest headlines -- as well as a couple hidden stories -- are reflected in this list of the best and worst ETFs so far in 2013. More
Middleby’s Shareholders Have Lost Their Marbles
Middleby's shareholders voted down CEO Selim Bassoul's 2013 compensation package -- a bad move, considering he's one of the best-performing CEOs out there. More
